Testosterone does not improve ovarian response in Bologna poor responders: a randomized controlled trial (TESTOPRIM)

被引:6
|
作者
Subira, Jessica [1 ,2 ]
Algaba, Anna [1 ]
Vazquez, Sheila [1 ]
Taroncher Dasi, Roser [1 ]
Molla Robles, Guillermo [3 ]
Monzo Fabuel, Susana [1 ]
Baydal, Virginia [1 ]
Ruiz Herreros, Amparo [1 ]
Garcia Camunas, Nuria [1 ]
Rubio Rubio, Jose Maria [1 ]
机构
[1] Univ Hosp La Fe, Reprod Med Res Grp, Assisted Reprod Unit, Spanish Clin Res Network SCReN, Avinguda Fernando Abril Martorell 106, Valencia 46026, Spain
[2] IVIRMA Valencia, Plaza Policia Local 3, Valencia 46015, Spain
[3] IVI Fdn, Edificio Biopolo, Valencia 46026, Spain
关键词
Follicular priming; IVF; Mature oocytes; Poor ovarian response; Testosterone; TRANSDERMAL TESTOSTERONE; IVF PATIENTS; GONADOTROPINS; PRETREATMENT; STIMULATION;
D O I
10.1016/j.rbmo.2021.05.021
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Research question: Does testosterone, either in a long or short course, before IVF increase the number of mature oocytes retrieved in poor ovarian response? Design: Single-centre, single-blinded, randomized controlled trial. Poor ovarian response is defined according to Bologna criteria. Sixty-three participants were included and assigned to three arms: group 1 (long testosterone [n = 17]) 12.5 mg/day testosterone gel for 56 days before ovarian stimulation; group 2 (short testosterone [n = 161) 12.5 mg/day testosterone gel for 10 days before ovarian stimulation; and group 3 (control, no intervention). Primary outcome was number of mature oocytes retrieved. Secondary outcomes included other cycle parameters (duration of stimulation, antral follicle count, number of follicles >16 mm, total oocytes retrieved and testosterone levels). Results: The number of mature oocytes retrieved did not differ between the three groups (2.16, 2.71 and 2.91, P = 0.719, groups 1, 2 and 3, respectively). No other significant differences were found in the remaining cycle parameters, except for testosterone levels at the beginning of ovarian stimulation, which were higher in both testosterone groups and relatively higher in group 2 (1.67 and 3.03, respectively versus 0.14 control group, P = 0.01). A Poisson regression model showed no significant differences for the primary outcome (group 3 versus group 2: 0.925, 95% CI 0.572 to 1.508, P = 0.753; group 3 versus group 1: 0.873, 95% CI 0.534 to 1.426, P = 0.587). Conclusions: The use of testosterone, even when applied for a prolonged period, does not improve the number of mature oocytes in poor ovarian response.
引用
收藏
页码:466 / 474
页数:9
相关论文
共 50 条
  • [41] Effect of acupuncture on women with poor ovarian response: a study protocol for a multicenter randomized controlled trial
    Huanfang Xu
    Chensi Zheng
    Liyun He
    Tongsheng Su
    Huidan Wang
    Yu Li
    Cui Zhao
    Cuilian Zhang
    Yang Bai
    Guoqing Tong
    Li Chen
    Fang Zhao
    Huisheng Yang
    Mingzhao Hao
    Yaqian Yin
    Li Yang
    Yigong Fang
    Baoyan Liu
    Trials, 21
  • [42] Effect of acupuncture on women with poor ovarian response: a study protocol for a multicenter randomized controlled trial
    Xu, Huanfang
    Zheng, Chensi
    He, Liyun
    Su, Tongsheng
    Wang, Huidan
    Li, Yu
    Zhao, Cui
    Zhang, Cuilian
    Bai, Yang
    Tong, Guoqing
    Chen, Li
    Zhao, Fang
    Yang, Huisheng
    Hao, Mingzhao
    Yin, Yaqian
    Yang, Li
    Fang, Yigong
    Liu, Baoyan
    TRIALS, 2020, 21 (01)
  • [43] Efficacy of the delayed start antagonist protocol for controlled ovarian stimulation in Bologna poor ovarian responders: a systematic review and meta-analysis
    Yang, Shuang
    Liu, Nenghui
    Li, Yanping
    Zhang, Lei
    Yue, Rongya
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 303 (02) : 347 - 362
  • [44] Authors' reply: Effect of dehydroepiandrosterone administration before IVF on the live birth rate in poor ovarian responders according to the Bologna criteria: a randomised controlled trial
    Wang, Ze
    Shi, Yuhua
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 129 (09) : 1611 - 1611
  • [45] Efficacy of the delayed start antagonist protocol for controlled ovarian stimulation in Bologna poor ovarian responders: a systematic review and meta-analysis
    Shuang Yang
    Nenghui Liu
    Yanping Li
    Lei Zhang
    Rongya Yue
    Archives of Gynecology and Obstetrics, 2021, 303 : 347 - 362
  • [46] Gonadotrophin-releasing hormone agonist protocol of controlled ovarian hyperstimulation as an efficient treatment in Bologna-defined poor ovarian responders
    Stimpfel, Martin
    Vrtacnik-Bokal, Eda
    Pozlep, Barbara
    Kmecl, Jerneja
    Virant-Klun, Irma
    SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE, 2016, 62 (04) : 290 - 296
  • [47] Testosterone therapy for women with poor ovarian response undergoing IVF: a meta-analysis of randomized controlled trials
    Noventa, Marco
    Vitagliano, Amerigo
    Andrisani, Alessandra
    Blaganje, Mija
    Vigano, Paola
    Papaelo, Enrico
    Scioscia, Marco
    Cavallin, Francesco
    Ambrosini, Guido
    Cozzolino, Mauro
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2019, 36 (04) : 673 - 683
  • [48] Testosterone therapy for women with poor ovarian response undergoing IVF: a meta-analysis of randomized controlled trials
    Marco Noventa
    Amerigo Vitagliano
    Alessandra Andrisani
    Mija Blaganje
    Paola Viganò
    Enrico Papaelo
    Marco Scioscia
    Francesco Cavallin
    Guido Ambrosini
    Mauro Cozzolino
    Journal of Assisted Reproduction and Genetics, 2019, 36 : 673 - 683
  • [49] Randomised controlled trial on the effect of clomiphene citrate and gonadotropin dose on ovarian response markers and IVF outcomes in poor responders
    Moffat, R.
    Hansali, C.
    Schoetzau, A.
    Ahler, A.
    Gobrecht, U.
    Beutler, S.
    Raggi, A.
    Sartorius, G.
    De Geyter, C.
    HUMAN REPRODUCTION, 2021, 36 (04) : 987 - 997
  • [50] Luteal estradiol versus follicular GnRH antagonist for ovarian follicular synchronization in POSEIDON poor responders: a multicentric randomized controlled trial
    Goel, K.
    Mantravadi, K. C.
    Gedela, D. R.
    HUMAN REPRODUCTION, 2024, 39